moneyheap
BSX · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Boston Scientific Corp. (BSX) stock moving?
Boston Scientific's Q3 2026 report (Oct 28) cut full-year adjusted EPS guidance to $3.16–$3.18 and triggered a wave of analyst actions. The stock fell from $45.06 to $42.43 on about 69.8M shares, roughly four times the usual volume, and has since recovered to $44.70 on Nov 10. Rating changes split the Street: TD Cowen, Jefferies, Barclays and Wells Fargo moved to Hold or Equal-Weight with $45–46 targets, Citigroup stayed Neutral at $44, while UBS ($57), RBC ($52), Leerink ($50), Canaccord and CCORF ($48) kept Buy-type ratings. Recent company news is constructive: positive six-month SIMPLAAFY primary endpoint data for WATCHMAN FLX Pro (Nov 2) and a $455M Blackstone co-funding deal for the Vitalyst heart pump (Nov 3), which supported a move to $45.82 on Nov 4 on 34.6M shares. Offsetting this, a law firm opened an investor investigation on Nov 6, and the pending Penumbra acquisition and the Jan 1, 2027 reorganization add execution risk. The stock is trading between the post-earnings low of about $42.4–42.8 and the recent high near $46, with volume fading toward the mid-teens of millions.
News behind the analysis
- Bronstein, Gewirtz & Grossman, LLC Announces Investigation into Boston Scientific CorporationA law firm opened an investigation into potential investor claims after the Q3 2026 results. No allegations have been filed.
- CCORF Maintains Buy Rating and $48 Price Target for Boston ScientificCCORF reaffirmed its Buy rating and $48 price target, about 7% above the Nov 10 close of $44.70.
- Boston Scientific and Blackstone Life Sciences Announce $455 Million Co-Funding AgreementBlackstone Life Sciences agreed to co-fund up to $455 million for development of the Vitalyst temporary heart pump system.
- Boston Scientific Announces Positive Results from SIMPLAAFY Clinical TrialThe SIMPLAAFY randomized trial of the WATCHMAN FLX Pro device met its six-month primary endpoints.
- Boston Scientific Reports Q3 2026 Financial Results and Updates Full-Year GuidanceQ3 sales were $5.138B and adjusted EPS $0.73. Full-year 2026 adjusted EPS guidance was lowered to $3.16–$3.18.
- TD Cowen Downgrades Boston Scientific to HoldTD Cowen cut its rating from Buy to Hold with a $46 price target after the Q3 report.
- Analysts Downgrade Boston Scientific Following Q3 EarningsJefferies, JPMorgan and Oppenheimer downgraded the stock or lowered targets after the Q3 2026 report.
- Jefferies Downgrades Boston Scientific to Hold, Lowers Price Target to $46Jefferies moved its rating to Hold and cut its price target to $46 after Q3 earnings.
- UBS Maintains Buy on Boston Scientific, Lowers Price Target to $57UBS kept its Buy rating but reduced its price target to $57 following the Q3 report.
About Boston Scientific Corp.
Boston Scientific is a Marlborough, Massachusetts maker of minimally invasive medical devices used by heart doctors, gastroenterologists, urologists and other specialists, with net sales of about $20 billion in 2025. It is known for its fast-growing heart-rhythm business, especially the Farapulse pulsed-field ablation system for atrial fibrillation and the Watchman device that closes off part of the heart to lower stroke risk.
How it makes money
It sells devices to hospitals and clinics around the world. These fall into two reporting segments: Cardiovascular, which is roughly 60% or more of sales (electrophysiology/ablation, Watchman, stents, heart-valve and vascular products), and MedSurg (endoscopy, urology, neuromodulation for pain and Parkinson's). The US brings in roughly 60% of revenue. Growth slowed sharply in Q3 2026, when sales rose only about 1.5% to about $5.1 billion; the company partly blamed a cybersecurity incident.
What usually moves BSX
- Adoption of Farapulse ablation and Watchman
- Clinical trial results and FDA approvals
- Hospital procedure volumes
- Operational disruptions such as the 2026 cyber incident
- Acquisitions and pricing and reimbursement changes